/LADX
LADX Stock - LadRx Corporation
Healthcare|BiotechnologyOTC
$0.12+0.00%
+$0.00 (+0.00%) • Dec 19
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.13
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LADX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.12 – $0.12
TARGET (TP)$0.14
STOP LOSS$0.11
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.51
52W High$2.40
52W Low$0.09
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-5,712 | $-11,835 | $-15,004 | $-13,978 | $-29,037 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-3,623,142 | $-3,824,000 | $-4,561,000 | $-12,077,000 | $-6,829,000 |
| Net Income | $-1,589,685,000 | $400,443 | $-4,201,000 | $-13,177,000 | $-6,701,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3210.89 | $0.68 | $-11.00 | $-35.52 | $-19.34 |
Company Overview
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
LADXBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-1.45
Q2 2025
EPS Surprise History
Q3 23
No data
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | — | — | — | — |
Q3 2025 | Aug 18, 2025 | — | — | — | — |
Q2 2025 | May 14, 2025 | — | $-1.45 | — | — |
Q1 2025 | Mar 28, 2025 | — | $0.67 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-1.67 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-2.59 | — | — |
Q2 2024 | May 15, 2024 | — | $0.38 | — | — |
Q1 2024 | Mar 27, 2024 | — | $-1.77 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-1.65 | — | — |
Q3 2023 | Aug 14, 2023 | — | $6.45 | — | — |
Q2 2023 | May 15, 2023 | — | $-3.00 | — | — |
Q1 2023 | Mar 20, 2023 | — | $-2.00 | — | — |
Q4 2022 | Nov 10, 2022 | — | $-3.00 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-1.79 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-3.32 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-24.02 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-4.41 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-3.22 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-3.51 | — | — |
Latest News
Loading news...
Frequently Asked Questions about LADX
What is LADX's current stock price?
LadRx Corporation (LADX) is currently trading at $0.12 per share. The stock has moved +0.00% today.
What is the analyst price target for LADX?
No analyst price targets are currently available for this stock.
What sector is LadRx Corporation in?
LadRx Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is LADX's market cap?
LadRx Corporation has a market capitalization of $0.00 billion, making it a small-cap company.
Does LADX pay dividends?
No, LadRx Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACBM
Acro Biomedical Co., Ltd.
$0.00
Mkt Cap: $0.0B
BIOIF
Biome Grow Inc.
$0.00
Mkt Cap: $0.0B
DNAG
DNAPrint Genomics, Inc.
$0.00
Mkt Cap: $0.0B
INSD
Instadose Pharma Corp.
$0.00
Mkt Cap: $0.0B
MEDVF
Medivolve Inc.
$0.00
Mkt Cap: $0.0B
MHTX
Manhattan Scientifics, Inc.
$0.00
Mkt Cap: $0.0B
MRPI
Mera Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
NNBP
Nanobac Pharmaceuticals, Incorporated
$0.00
Mkt Cap: $0.0B
NSPDF
Naturally Splendid Enterprises Ltd.
$0.04
Mkt Cap: $0.0B
USRM
U.S. Stem Cell, Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to LADX for comparison